The present dose-escalating randomized placebo-controlled Phase I/II trial aimed to investigate antiviral activity and safety of α-GalCer as a novel class of treatment for chronic hepatitis B patients. Methods: Patients were randomly assigned to 0.1 µg/kg (n=8), 1 µg/kg (n=6) or 10 µg/kg (n=6) α-GalCer or placebo (n=7) treatment. Results: Almost all α-GalCer-treated patients showed a rapid and strong decrease in natural killer T-cell (NKT) numbers. Patients with high baseline NKT numbers showed immune activation, including natural killer cell activation, increased serum tumour necrosis factor-α and interleukin-6 levels, and development of fever. Three patients demonstrated a transient decrease in hepatitis B virus (HBV) DNA. Only one α-GalCer-treated patient had a sustained decrease in HBV DNA at the end of follow-up. Four patients discontinued therapy because of fever shortly after drug administration. No significant side effects were observed. Conclusions: α-GalCer (0.1-10 µg/kg) used as monotherapy for chronic hepatitis B infection resulted in a strong decrease of NKTs, but did not clearly affect HBV DNA and alanine aminotransferase levels. α-GalCer was poorly tolerated and is unlikely to be suitable as an alternative monotherapy to the current treatment regimen.
Chronic hepatitis B remains a major health problem. Worldwide, 2 billion people show evidence of infection with hepatitis B virus (HBV) and it chronically affects an estimated 400 million people [1] . Approximately 15-40% of these individuals will develop serious complications such as liver cirrhosis and hepatocellular carcinoma [2] . Pegylated interferons (IFNs) have been shown to induce a sustained virological response in approximately 35-45% of patients [3] [4] [5] . Because of the importance of immune control over the HBV, immunomodulatory drugs are of special interest in the treatment of chronic hepatitis B infection.
The glycosphingolipid α-galactosylceramide (α-GalCer) has been shown to induce potent antiviral as well as antitumour immune responses [6] [7] [8] . α-GalCer, originally derived from marine sponge, activates invariant natural killer T-cells (iNKTs), which recognize α-GalCer in the context of the major histocompatibility complex-like molecule CD1d [9] . iNKTs constitute a distinct lymphocyte subpopulation characterized by expression of both natural killer (NK) receptors and a restricted T-cell receptor repertoire, which in humans consists of a Vα24 chain preferentially paired to Vβ11 [10] . Upon activation, these cells rapidly secrete large amounts of both T-helper (Th)-1 and Th-2 cytokines, which subsequently enhance innate as well as adaptive immune cells [11] [12] [13] . Besides their pivotal role in antitumour and antiviral immune responses, natural killer T-cells (NKTs) have also been implicated in several other antimicrobial immune responses, as well as in autoimmunity and allergy.
Original article α-Galactosylceramide in chronic hepatitis B infection: results from a randomized placebo-controlled Phase I/ II trial

Introduction
Approximately 20-30% of intrahepatic lymphocytes consist of NKTs [14] . Interestingly, NKTs activated by α-GalCer have been shown to inhibit HBV replication in HBV transgenic mice [15] . This antiviral effect of α-GalCer is associated with a rapid induction of IFN-γ and IFN-α/β in the liver even before a significant number of inflammatory cells are recruited to the liver, suggesting that intrahepatic NK cells and NKTs are involved in this process [15, 16] . In addition, it has been suggested that α-GalCer also exerts direct antiviral activity against HBV [17] .
KRN7000 is a synthetic α-GalCer that has been most frequently used in experimental mouse studies, but also in some human oncology trials and in hepatitis C infection [18] [19] [20] [21] [22] . Also in the human setting, α-GalCer administration has been shown to induce immune activation in individuals, which depended on pretreatment circulating iNKT numbers [19] . The aim of the present study was to investigate the safety, tolerability and the antiviral effect of α-GalCer for the treatment of patients with chronic hepatitis B infection.
Methods
Patients
Male and female patients aged 18-70 years with either hepatitis B e antigen (HBeAg)-positive or HBeAgnegative chronic hepatitis B infection were enrolled. All patients had an HBV DNA level >10 5 copies/ml at screening and two alanine aminotransferase (ALT) values of >1.2× the upper limit of normal (ULN) within 8 weeks before initiation of treatment. The ULN for ALT was 40 U/l for males and 30 U/l for females. A liver biopsy obtained within 3 years prior to screening, consistent with chronic hepatitis B infection and without cirrhosis, was required.
Exclusion criteria were the evidence of decompensated liver disease (as indicated by bilirubin >20 µmol/l, serum albumin <35 g/l, prothrombin time prolonged by >3 s, history of bleeding oesophageal varices, ascites or hepatic encephalopathy), ALT level >10×ULN, pregnancy or the inability to practice adequate contraception, clinically significant or major illnesses, history of autoimmune disease, systemic treatment with IFN-α, antiviral agents or another investigational drug within 3 months prior to enrolment in the study, immune suppressive treatment, pre-existing severe cytopaenia (that is, haemoglobin <7 mmol/l, white blood cell count <3.0×10 9 cells/l, lymphocytes <0.5×10 9 cells/l or platelets <100×10 9 cells/l), evidence of hepatocellular carcinoma as indicated by α-fetoprotein >50 ng/ml and/or ultrasound demonstrating a mass suggestive of liver cancer, and other acquired or inherited causes of liver disease.
The study was approved by the ethics committees at our hospital (Erasmus MC University Medical Center, Rotterdam, the Netherlands) according to the Declaration of Helsinki, and all patients gave written informed consent before enrolment.
Study design
This Phase I/II dose-escalation trial was performed in a randomized, double-blind and placebo-controlled manner. Patients with chronic hepatitis B who met the inclusion criteria were assigned to receive three dosages of α-GalCer (KRN7000 [(2S,3S,4R) 
octadecanetriol]; Kirin Pharma Co., Ltd, Gunma, Japan) or placebo intravenously, with intervals of 4 weeks. Patients were enrolled into three dose-escalating groups with 11 patients in the first group (8 verum and 3 placebo) and 8 patients in the second and third group (both 6 verum and 2 placebo; Figure 1 ). After enrolment, patients were randomized to receive either α-GalCer or placebo. The dosage of α-GalCer was 0.1 µg/kg body weight in the first, 1 µg/kg in the second and 10 µg/kg in the third group. After completion of 8 weeks of treatment, with injections at 0, 4 and 8 weeks, patients were monitored without further therapy for an additional 16 weeks.
Dose increase to the next cohort was decided after evaluation by a safety review board of all the safety data collected on all the patients who had completed 3 weeks after the first injection in the preceding dose cohort. The safety review board consisted of three experienced hepatologists who were not involved in the study.
Study objectives
The primary objective of the study was to evaluate the safety and tolerability of the three increasing doses of α-GalCer. The secondary objective was to evaluate the effectiveness of α-GalCer, immunological responses, reduction of HBV DNA and ALT normalization.
Biochemical and virological assessments
The extent of liver inflammation was determined by measuring serum ALT levels. HBV DNA levels were measured using an in-house developed TaqMan realtime PCR assay (dynamic range 400-10 10 copies/ml) [23] . The Eurohep HBV DNA standard was used for validation of HBV DNA levels [24] . HBeAg, hepatitis B surface antigen (HBsAg), antibodies against HBeAg (anti-HBe) and antibodies against HBsAg (anti-HBs) were measured using a commercially available immunoassay (Abbott Laboratories, Abbott Park, IL, USA).
Immunology testing
Lymphocyte numbers were determined by adding fixed volumes of FlowCount™ fluorospheres (BeckmanCoulter, Miami, FL, USA) to the leukocytes after erythrocyte lysis (BD Biosciences, San Jose, CA, USA) just before flow cytometric evaluation. Fluorescenceactivated cell sorting (FACS) analysis was performed using monoclonal antibodies against CD3 (SK7), CD4 (SK3), CD8α (SK1), CD45 (2D1), CD69 (L78) and the isotype controls mouse IgG1 (X40) and IgG2a (X39; all purchased from BD Biosciences), Vβ11 (C21), Vα24 (C15) and CD8β (2ST8.5H7; all from Immunotech, Marseille, France), and CD56 (MOC-1; IQ products, Groningen, the Netherlands) before and 2 and 7 days after each injection as well as at the end of treatment (EOT; day 84) and at the end of follow-up (EFU; day 168). For staining with α-GalCer or vehicle-loaded CD1d tetramers (Gemini Science Inc., San Diego, CA, USA), 150 µl of whole blood was incubated with the tetramers for 10 min at 37°C, followed by staining for CD3 and Vα24 and erythrocyte lysis. Whole blood analysis of myeloid and plasmacytoid dendritic cell (DC) numbers was performed, as described previously [25] , before and 7 days after each injection as well as at EOT and EFU. Flow cytometric analysis was performed on a FACS Calibur using CELL Quest software (BD Biosciences).
Serum levels of IFN-γ, tumour necrosis factor (TNF)-α, interleukin (IL)-6, IL-1β, IL-10, IL-5 and granulocyte macrophage colony-stimulating factor (GM-CSF) were measured by flow cytometry using the CBA Human Soluble Protein Flex Set system (BD Biosciences) and ELISA (IFN-γ and TNF-α; R&D Systems, Abingdon, UK) before, at 4 h and at 2 days after injection in all patient groups. Depending on the number of cells, IL-12 production by polyI:C (20 µg/ml; Sigma-Aldrich, St Louis, MO, USA) and IFN-γ (1,000 U/ml; Strathmann Biotech, Hamberg, Germany) stimulated BDCA1 + myeloid DCs (mDCs) were examined as described previously [25] . These mDCs were isolated from peripheral blood mononuclear cells by negative depletion with anti-CD19-conjugated microbeads, followed by positive selection using anti-BDCA1-PE and PE-conjugated microbeads using the mini-MACS system (Miltenyi Biotec, Bergisch Gladbach, Germany), and stimulated in the presence of GM-CSF during 24 h [25] . mDC function was analysed in all patient groups (placebo n=5, level 1 n=5, level 2 n=3 and level 3 n=2) before and 7 days after start of treatment and at EOT.
Statistical analyses
Because of the explorative character of the study, power analysis was not considered. Patients were randomized by the Clinical Research Bureau of the Erasmus MC University Medical Center Rotterdam (Rotterdam, the Netherlands) using a computer generated randomization 
Results
Patients
A total of 30 patients were screened between August 2003 and January 2006 at the Erasmus MC University Medical Center Rotterdam. Of the 30 patients, 27 met the criteria for enrolment into the study. In total, eight patients were allocated to a dose of 0.1 µg/kg body weight (dose level 1), six were allocated to 1 µg/kg body weight (dose level 2), six were allocated to 10 µg/ kg body weight (dose level 3) and seven to placebo ( Figure 1 ). One patient in the highest dosage group withdrew his informed consent before study medication was administered.
The median age at inclusion was 35 years (range 21-58). At baseline, the median ALT level was 103.5 IU/l (range 35-356) and the median HBV DNA level was 8.1 log 10 copies/ml (7.4 log 10 IU/ml; range 5.0-9.5 log 10 copies/ml). Further demographics and baseline characteristics for the different dose levels are given in Table 1 . There were no significant differences between the patient characteristics of different treatment groups prior to therapy.
NKT numbers decrease after α-GalCer administration
At baseline, the number of circulating NKTs, defined as CD3 + Vα24 + Vβ11 + cells, did not significantly differ between the groups (Figure 2 ). The first administration of α-GalCer induced a rapid decrease in circulating NKTs in all dose levels (day 0 versus day 2; dose level 1 P=0.0156, level 2 P=0.0313 and level 3 P=0.1250), which was followed by a recovery of NKT numbers ( Figure 2B and 2C) . Although less pronounced, this decrease in NKT numbers was also observed after the second and third administration of α-GalCer ( Figure  2B ). Furthermore, albeit not significantly different, the number of NKTs was still decreased at the EOT (day 84) and approached baseline levels at the EFU (day 168). The NKT numbers in patients receiving placebo did not significantly differ during the study period (Figure 2A, 2B and 2C ). Similar findings were observed with α-GalCer CD1d-tetramer staining, which was evaluated in 201 blood samples (data not shown).
Of note, all patients exhibiting high baseline NKT levels that received ≥1 µg/kg α-GalCer developed fever and severe rigors 1 h to 2 days after drug administration (see Safety; Figure 2D ). NKT subset analysis in these patients revealed that after the first administration of α-GalCer, the proportion of CD4 + NKTs decreased and the proportion of CD8 + NKTs increased, whereas in placebo-treated patients with high baseline NKT levels, the proportion of NKT subsets did not differ.
Analysis of circulating NK cells, T-cells and DCs
To evaluate α-GalCer induced indirect immune activation, peripheral blood NK cells, T-cells and DCs were analysed. The analysis of circulating NK cells revealed that α-GalCer treatment significantly changed the number of NK cells 2 days post-injection (Figure 3) . Surprisingly, in patients receiving 0.1 or 1 µg/ kg α-GalCer, NK cell numbers significantly decreased (P=0.02 and P=0.03, respectively), whereas the highest dosage induced an increase in NK cells (P=0.03). Activated NK cells, as defined by CD69 + cells, were observed in all treated patient groups, but the most pronounced 
05). Significant differences in circulating T-cells and DCs were not observed.
Of note, the only patient with a sustained decrease in HBV DNA levels during treatment demonstrated an increased number of circulating myeloid DCs at the EOT (day 0, 0.32% and day 84, 0.74%). Moreover, these myeloid DCs displayed an increased capacity to produce IL-12 (t=0 60 pg/ml and t=84 1,478 pg/ml), which is in line with our previous findings demonstrating that viral load reduction increases the number of circulating myeloid DCs as well as their function [25] .
Serum cytokine levels
Serum cytokine levels were determined at baseline, 4 h and 2 days after each α-GalCer administration. Cytokine levels remained undetectable in the patient group with low NKT numbers; however, in five of nine patients with high NKT levels, a transient increase in TNF-α was observed. The patient exhibiting the highest TNF-α level (35 pg/ml) experienced severe fever shortly after α-GalCer administration (see Safety). In addition, the patients exhibiting a period of fever shortly after α-GalCer administration demonstrated an increase in IL-6 from 2 ±3 pg/ml at baseline to 719 ±906 pg/ml 4 h after drug administration that returned to baseline levels at day 2. No detectable levels of IFN-γ, IL-1β, IL-10, IL-5 and GM-CSF were observed in serum of those patients.
Virological and biochemical response
No significant decreases in HBV DNA following the first administration of α-GalCer were observed in any of the three dosages groups (Figure 4) . Four patients showed a >0.5 log 10 copies/ml decrease in HBV DNA levels following the first administration (1 µg/kg n=2 and 10 µg/kg n=2) with a median decrease in the first week of 1.09 log 10 copies/ml (range 0.54-2.96; n=4) from baseline.
Among the whole group during follow-up of 168 days, no statistically significant changes in HBV DNA level were observed among the different dose levels (Figure 4 ). One patient in dose level 2, who displayed a low circulating NKT number and experienced a viral load decrease of 0.54 log 10 copies/ml 1 week after the first injection, had a sustained drop in HBV DNA level of 4.02 log 10 copies/ml at the EFU. The other three patients with a decrease in HBV DNA level after the first administration, of whom one patient displayed low and two patients displayed high baseline NKT numbers, had no decrease after the second and third injection of α-GalCer and HBV DNA levels returned to baseline. HBeAg seroconversion was not observed in any of the α-GalCer-treated patients. One HBeAg-positive patient in the placebo group had an HBeAg seroconversion and a decrease in HBV DNA of 4.48 log 10 copies/ml at the EFU. There were also no clear and significant differences in the ALT values over time in the three different dose levels of α-GalCertreated patients compared with placebo ( Figure 5 ).
Safety
A total of 122 adverse events were reported in this study. The most frequent reported adverse events were flu-like symptoms: fever (78%) and headache (63%). Other frequently reported side effects were abdominal pain (37%), and nausea and vomiting (30%; Table 2 ). Two patients had an ALT flare >10×ULN, both not resulting in hepatic decompensation. Four patients (patient in the 1 µg/kg dose level and three in the 10 µg/ kg dose level group) discontinued therapy prematurely because of an episode of fever and severe rigors 1 h to 2 days after drug administration one. All these episodes of fever resolved within 1 week after onset.
Discussion
This Phase I/II randomized, double-blind and placebocontrolled trial provides unique data on the antiviral activity and safety of the immunomodulating glycosphingolipid α-GalCer for the treatment of chronic hepatitis B infection. In this trial, three administrations of α-GalCer with a 28-day interval were given in chronic hepatitis B patients in three different dose levels. Although almost all patients responded to α-GalCer as shown by a rapid and strong decrease in NKT numbers, proper immune activation with clear and sustained antiviral activity was, however, not observed. As expected from literature, iNKTs rapidly disappeared from the circulation upon α-GalCer administration. This decrease in circulating iNKT cell numbers was observed after each α-GalCer injection but also rapidly returned close to pretreatment values. Whether circulating NKTs die or migrate to the liver, as described previously [26, 27] , remains to be determined. In contrast to the study of Veldt et al. [22] , in which chronic hepatitis C patients showed only a moderate decrease in circulating iNKT numbers upon α-GalCer treatment, the current study on chronic hepatitis B patients showed a profound decrease in circulating iNKTs upon administration of similar doses of α-GalCer. Therefore, the effect of α-GalCer treatment on the immune system in the current study surpasses the effects observed in α-GalCer-treated hepatitis C patients. The initial number of the circulating iNKTs in chronic hepatitis B patients appears to be comparable to the number present in healthy controls and chronic hepatitis C patients [19, 22, 28] . The reduction of circulating iNKTs in chronic hepatitis B patients was most pronounced after the first injection of α-GalCer and seemed to decrease over time. This might suggest that the potential antiviral effect of α-GalCer in chronic hepatitis B patients diminishes over time, which might be related to the decreasing iNKT pool during treatment. In line with previous studies, we observed the strongest immune-activating effects in patients with high NKT levels [19, 22] . We defined the iNKT-high group by using the median number of circulating iNKTs in patients (1,100 CD3 + cells). This NKT-high group showed stronger immune activation upon α-GalCer administration than the other patients as demonstrated by stronger iNKT decreases, transient rises in serum TNF-α and IL-6 levels, and increased circulating activated NK cells. None of the immunological parameters tested showed clear α-GalCer dose-dependent effects; however, some dose-response effects were observed in relation to circulating NK cell numbers and the development of fever. Patients with high levels of circulating iNKTs developed fever, as reported previously [19] , but only when treated with at least 1 µg/ kg α-GalCer. The specific, but transient, increase in the proportion of CD8 + NKTs in these patients might reflect a shift towards a more pronounced Th-1 phenotype [29] , but also IFN-γ serum levels remained undetectable in these patients.
Although the biological activity of α-GalCer in chronic hepatitis B patients seemed to be superior compared with chronic hepatitis C patients, α-GalCer did not significantly affect HBV DNA or ALT levels. Four patients treated with α-GalCer had a pronounced decreases in HBV DNA in the first week of treatment, but this decrease was not sustained and was also not observed after the second and third administration of α-GalCer. One patient in dose level two had a sustained drop in HBV DNA at the EFU (4 log 10 copies/ml reduction). Because α-GalCer is thought to act through an immune-mediated mechanism, the study population might have been too heterogeneous to observe clear α-GalCer-induced immune regulation as demonstrated by differences in HBeAg status, ALT levels, HBV genotypes and presumed route of infection, which might reflect different immunological stages in HBV infection as well as different immunological activities. In HBV transgenic mice, α-GalCer was able to inhibit HBV replication by directly activating NKTs and by consequent activation of NK cells to secrete antiviral cytokines, such as IFN-γ and IFN-α/β in the liver [15] . However, compared with chronic HBV infection in patients, mice that express products of the HBV genome and also show signs of HBV replication do not have an active HBV infection and contain disproportional high numbers of intrahepatic NKTs, making these mouse studies difficult to translate to the human situation. Although we were not able to study intrahepatic NK cell activation, patients with high circulating NKT levels did show enhanced levels of activated circulating NK cells upon α-GalCer injection, which is in line with previous reports [19, 30] . This enhanced activation status of NK cells did not result in significant increases in serum IFN-γ levels and/or HBV DNA decrease. We did notice signs of immune activation as determined by increased serum IL-6 levels in the patients exhibiting an episode of fever and severe rigors. This suggests that α-GalCer is able to induce immune activation in the liver because IL-6 is one of the primary inducers of the acute phase response in the liver. Four α-GalCer-treated patients discontinued therapy early because of an episode of fever shortly after drug administration. All these episodes resolved spontaneously. These side effects limited further development of treatment with α-GalCer in chronic hepatitis B patients. Furthermore, there is no clear and consistent effect of α-GalCer on HBV DNA and ALT levels. This can be a result of the relatively low NKT levels in humans compared with mice, where α-GalCer was able to inhibit HBV replication [15] . Serious side effects were not observed in a trial with α-GalCer treatment in patients chronically infected with hepatitis C [22] . This suggests that there is a different NKT response in chronic hepatitis B patients.
A higher dosage of α-GalCer might be more effective, but the α-GalCer dosage is probably limited by its side effects. Alternatively, administration of α-GalCer bound to DCs has been shown to be much more potent than α-GalCer itself and seems to be well tolerated [31] [32] [33] . Nevertheless, previous studies on α-GalCer in humans have shown immune responses with the relatively low levels of α-GalCer used in this trial [19] .
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